KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Novavax (NVAX) over the last 15 years, with Q3 2025 value amounting to $494.9 million.

  • Novavax's Short-term Investments rose 4733.51% to $494.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.9 million, marking a year-over-year increase of 4733.51%. This contributed to the annual value of $392.9 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Novavax's Short-term Investments stood at $494.9 million, which was up 4733.51% from $358.6 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Short-term Investments ranged from a high of $494.9 million in Q3 2025 and a low of $2.2 million during Q1 2021
  • For the 3-year period, Novavax's Short-term Investments averaged around $346.0 million, with its median value being $369.4 million (2024).
  • In the last 5 years, Novavax's Short-term Investments plummeted by 9608.52% in 2021 and then soared by 4733.51% in 2025.
  • Novavax's Short-term Investments (Quarter) stood at $2.2 million in 2021, then soared by 17361.69% to $392.9 million in 2024, then rose by 25.96% to $494.9 million in 2025.
  • Its Short-term Investments was $494.9 million in Q3 2025, compared to $358.6 million in Q2 2025 and $468.1 million in Q1 2025.